PBE news

Invesco Biotechnology & Genome · Biotechnology · United States · Genomics & Biotech Innovation

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Scienmag: Latest Science and Health News · 28 Oct 2026, 18:47 UTC
Nanopore Sequencing Delivers Full Pediatric Brain Tumor Workup in a Single
5.4% of PBE
Seeking Alpha · 28 Oct 2026, 20:02 UTC
Biogen anticipates $250M of run rate synergies by end of 2027 as it raises 2026 non-GAAP EPS to $12.20-$13 (NASDAQ:BIIB) | Seeking Alpha
5.1% of PBE
Seeking Alpha · 28 Oct 2026, 20:00 UTC
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript | Seeking Alpha
5.1% of PBE
Market Screener · 28 Oct 2026, 12:21 UTC
United Therapeutics Corporation Receives FDA Clearance To Proceed With Clinical Trial For Treprostinil-Iloprost SMI In Pulmonary Arterial Hypertension
6.3% of PBE
Where to buy PBE
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
RTTNews · 28 Oct 2026, 11:38 UTC
United Therapeutics Gets FDA Clearance To Begin Trial Of Inhaled PAH Therapy
6.3% of PBE
Seeking Alpha · 28 Oct 2026, 19:01 UTC
Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-10-28 | Seeking Alpha
5.1% of PBE
Where to buy PBE
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Investing.com · 28 Oct 2026, 11:12 UTC
United Therapeutics gets FDA nod for PAH combination therapy trial By Investing.com
6.3% of PBE
wallstreet:online · 28 Oct 2026, 11:05 UTC
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
6.3% of PBE
Investing.com · 28 Oct 2026, 15:42 UTC
Incyte earnings up next: Analysts eye loss amid pipeline gains By Investing.com
4.9% of PBE
Investing.com · 28 Oct 2026, 13:52 UTC
Earnings call transcript: Biogen beats Q3 2026 estimates as growth portfolio expands By Investing.com
5.1% of PBE
Market Screener · 28 Oct 2026, 14:41 UTC
Adagene Inc. Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte?S Inca33890 in Patients with Microsatellite Stable Colorectal Cancer
4.9% of PBE
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
4.7% of PBE
The Wall Street Journal · 28 Oct 2026, 11:09 UTC
Biogen Swings to Loss, Logs Higher Sales
5.1% of PBE
Seeking Alpha · 28 Oct 2026, 11:04 UTC
Biogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) | Seeking Alpha
5.1% of PBE
Bloomberg Business · 28 Oct 2026, 10:15 UTC
Biogen Sales Top Estimates With Help From Newly Acquired Drugs
5.1% of PBE
Investing.com · 28 Oct 2026, 10:14 UTC
Biogen beats Q3 estimates, raises guidance floor on growth By Investing.com
5.1% of PBE
The Manila times · 28 Oct 2026, 11:11 UTC
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
4.9% of PBE
Investor's Business Daily · 28 Oct 2026, 10:10 UTC
Biogen Makes A Solid Return 'To Growth' -- What To Know
5.1% of PBE
Reuters · 28 Oct 2026, 10:09 UTC
Biogen beats third-quarter results on strength in rare disease drugs
5.1% of PBE
Seeking Alpha · 28 Oct 2026, 11:43 UTC
Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued (NASDAQ:REGN) | Seeking Alpha
4.8% of PBE

PBE news

Where to buy PBE

Where to buy PBE